NU SKIN ENTERPRISES, INC. annual report, FY2023

Nu Skin Enterprises, Inc. — FY2023 Form 10-K

Reporting period: Fiscal year ended December 31, 2023; this is an annual report, not a standalone fourth-quarter filing. Nu Skin develops and sells beauty and wellness products through direct selling in nearly 50 markets. Its Rhyz arm includes manufacturing and other consumer and technology businesses.

Financial performance

Metric	FY2023	FY2022
Revenue	$1.969 billion	$2.226 billion
Gross profit / margin	$1.357 billion / 68.9%	$1.595 billion / 71.7%
Operating income / margin	$48.3 million / 2.4%	$110.8 million / 5.0%
Net income	$8.6 million	$104.8 million
Diluted EPS	$0.17	$2.07
Cash from operations	$118.6 million	$108.1 million

• Revenue declined 12% reported and 9% at constant currency; currency movements reduced FY2023 revenue by 3% versus FY2022. Net income fell 92%.
• Gross margin contracted 2.8 percentage points. Management cited a $65.7 million incremental inventory write-off following a product-portfolio reset, compared with $26.9 million in FY2022, and a larger revenue mix from lower-margin Rhyz manufacturing.
• Operating cash flow increased despite lower earnings, partly because of the timing of accrual payments. Capital expenditures were $58.5 million; cash used in investing was $134.5 million, including $77.3 million for acquisitions.
• Year-end cash and cash equivalents were $256.1 million; current investments were $11.8 million. Working capital was $373.0 million, down from $400.6 million.
• Debt totaled $505 million gross at year-end: $385 million term loan and $120 million revolver borrowings. The balance-sheet carrying amount was approximately $503 million after debt issuance costs. The company reported compliance with its debt covenants. Interest expense was $25.6 million, up from $13.5 million.
• The effective tax rate was 67.7%, versus a tax benefit and negative 17.8% effective rate in FY2022. Management attributed the increase mainly to U.S. restructuring charges reducing the ability to use foreign tax credits; it recorded an additional $6.1 million valuation allowance.

Business trends and material changes

• Core Nu Skin segment revenue fell 15% to $1.753 billion. Every geographic Nu Skin segment reported lower full-year revenue: declines ranged from 2% in Hong Kong/Taiwan to 22% in the Americas and Southeast Asia/Pacific.
• Rhyz revenue grew 41% to $216.6 million, or 11% of reported revenue. Manufacturing revenue rose 21%; Rhyz Other revenue increased substantially from a small base and acquisitions. Rhyz overall reported a segment contribution loss of $8.2 million, including a $20.6 million loss in Rhyz Other.
• At year-end, Customers declined 15% to 977,039, Paid Affiliates declined 30% to 166,886, and Sales Leaders declined 10% to 44,059. Management noted that certain fourth-quarter Paid Affiliate declines in several markets reflected tighter eligibility requirements for rewards.
• New offerings generated reported sales of approximately $87.5 million for ageLOC TRMe and $62.2 million for ageLOC WellSpa iO in 2023. Rhyz growth partly offset weakness in the core business.
• The company acquired 100% of Beauty Biosciences for $75 million net of cash acquired and 60% of LifeDNA in 2023. The acquisitions contributed $10.6 million of revenue after acquisition dates; BeautyBio purchase accounting was not finalized at year-end.

Outlook, management commentary and risks

• Management did not provide a full-year 2024 revenue or earnings forecast in the supplied filing text. It anticipates a 2024 effective tax rate of approximately 25%–35% and capital expenditures of $40–$60 million.
• A new workforce-reduction plan adopted in the fourth quarter of 2023 is expected to incur $15–$25 million of cash severance charges and be substantially completed in the first half of 2024. The company recorded $10 million of charges in 2023. It also reported $19.8 million of FY2023 restructuring and impairment expense, compared with $48.5 million in FY2022.
• In February 2024, the board reduced the quarterly dividend from $0.39 to $0.06 per share, expected to preserve approximately $65 million annually for growth initiatives. The company paid $77.6 million in dividends during 2023 and repurchased $13.0 million of shares.
• Management cited inflation, constrained discretionary spending, challenging economic conditions in Mainland China, the ongoing digital and social-commerce transformation, and foreign exchange as headwinds. Digital transformation requires significant investment and may not achieve expected adoption or returns.
• Mainland China remains subject to extensive regulatory scrutiny and restrictions; authorities have not issued new direct-selling licenses since 2019. Nu Skin is evaluating possible changes to its China compensation model, which could negatively affect sales.
• Material risks include direct-selling and product-claims regulation, actions by independent sales representatives, social-platform restrictions, product registration and supply constraints, foreign-currency and repatriation exposure, cybersecurity and privacy, acquisitions, and debt-covenant capacity. The filing describes ordinary-course legal and regulatory matters but provides no clear quantified estimate of potential losses in the supplied text.
• PwC issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective as of December 31, 2023. The auditor identified income taxes as a critical audit matter. Acquired LifeDNA and BeautyBio were excluded from the internal-control assessment.

Investor verification priorities

1. Verify the drivers and potential persistence of the sharp decline in core revenue, customer and affiliate counts, and earnings.
2. Assess whether the $65.7 million inventory write-off and portfolio narrowing adequately address excess or obsolete inventory, and whether further charges may arise.
3. Review debt repayment capacity, variable-rate exposure, covenant headroom, and the effect of the reduced dividend on capital allocation.
4. Track Rhyz profitability and acquisition integration, particularly BeautyBio’s finalized purchase accounting and the losses in Rhyz Other.
5. Monitor Mainland China regulatory developments, sales-compensation changes, and the company’s ability to maintain licenses and product registrations.
6. Evaluate whether digital transformation and new product launches can stabilize sales and rebuild the declining affiliate and customer base.